Jubilant Life Sc Q2 PAT up 92% at Rs 152 cr
- Rail Budget 2015: No hike in passenger fares, Prabhu promises modern rail network
- Rail Budget: Ally Shiv Sena not satisfied, but Mulayam says Prabhu has done a 'good job'
- Rail Budget futuristic and passenger centric: PM Modi
- PDP, BJP thrash out differences; all clear for Mufti-Modi meeting tomorrow
- Hummer horror: Senior policeman suspended for secretly meeting Kerala businessman
Jubilant Life Sciences today reported 92 per cent increase in profit after tax for the second quarter ended September at Rs 152 crore, boosted by gains from currency fluctuation.
The company had posted profit after tax of Rs 79 crore in the same period last fiscal, Jubilant Life Sciences said in a statement.
Total income from operations stood at Rs 1,225 crore, up 16 per cent from Rs 1,055 crore in the year-ago quarter.
During the quarter, the company had a net gain of Rs 49 crore as exceptional items mainly benefiting from the currency movement of rupee against dollar.
Commenting on the results, company Chairman & Managing Director Shyam S Bhartia and Co-Chairman & Managing Director, Hari S Bhartia said: "Continued focus on enhancing market shares across business lines, new product launches in both segments and enhanced capacity utilisation would drive achievement of annual guidance given earlier."
The pharmaceuticals segment clocked income from operations of Rs 650 crore, up 17 per cent from the same period last fiscal, and contributed 53 per cent to the revenue mix, the company said.
Income from the life science ingredients vertical stood at Rs 575 crore, up 15 per cent from the corresponding quarter last fiscal and contributed 47 per cent to the overall revenue.
The company said during the period under review, revenue from North America was at Rs 512 crore, up 20 per cent from the same period last fiscal. Revenues from Europe and Japan stood at Rs 240 crore, up 29 per cent.
The domestic revenues stood flat at Rs 337 crore, the company said.
On the outlook, Jubilant Life Sciences said in FY13 it expects to maintain its guidance of achieving over 20 per cent revenue growth.
"The company is confident of achieving this growth on account of new product launches and expansion in new territories by the pharmaceutical products businesses of APIs, generics and speciality pharma followed by higher utilisation of new capacities in life science ingredients and CMO business," it added.